Exenatide Versus Glibenclamide in Patients with Diabetes

Derosa, Giuseppe; Maffioli, Pamela; Salvadeo, Sibilla A T; Ferrari, Ilaria; Ragonesi, Pietro D.; Querci, Fabrizio; Franzetti, Ivano; Gadaleta, G; Ciccarelli, Leonardina; Piccinni, Mario N.; D’Angelo, Angela; Cicero, Arrigo F G

doi:10.1089/dia.2009.0141

Cited by 120 publications

(99 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One trial compared GLP-1 agonist (exenatide) with placebo on a background of basal insulin with oral anti-diabetic drugs [23]. One study compared GLP-1 agonist (exenatide) with glibenclamide on patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin [24]. One trial compared GLP-1 agonist (exenatide) with insulin glargine on metformin-treated patients with type 2 diabetes [25].…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Mazidi

Karimi

Rezaie

et al. 2017

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials Article (Accepted Version) http://sro.sussex.ac.uk Mazidi, Mohsen, Karimi, Ehsan, Rezaie, Peyman and Ferns, Gordon A (2016) Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications. ISSN 1056-8727 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/61270/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version. Copyright and reuse:Sussex Research Online is a digital repository of the research output of the University.Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I 2 index. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator. ÔØ Å ÒÙ×Ö ÔØ A C C E P T E DInternational Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868.Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD -2.14 (mg/dL), 95% CI -3.51, -0.78, P=0.002; I 2 96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD -2.14(mg/dL), 95% CI -3.51, -0.78, P=0.002; I 2 96.1%), indicating that our results could not be solel...

show abstract

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…The number of participants included in studies ranged from 20 [26] to 117 [22]. The range of age participants was from 18 years [24] to 69 years [21]. Moreover, each of these studies had its own inclusion criteria which are listed in Table 1.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Mazidi

Karimi

Rezaie

et al. 2017

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

show abstract

“…Two studies comparing exenatide with a SU in combination with metformin found similar decreases in HbA1c (-1.2% to −1.5% versus -1.4% to −1.8%) and FBG [-27 and −28 to −32 mg/dl (-1.5 and −1.55 to −1.77 mmol/liter)]. However, exenatide resulted in significant weight reduction while SUs were weight neutral or resulted in weight gain [Derosa et al 2010[Derosa et al , 2011. Exenatide also demonstrated greater durability than glimepiride with fewer treatment failures (41% versus 54%) and longer duration before treatment failure (180 weeks versus 142 weeks) when added to metformin [Gallwitz et al 2012 [Pratley et al 2010].…”

Section: Short-acting Glp-1 Rasmentioning

confidence: 88%

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

Harris

McCarty

2014

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first-and secondline diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin. Greater glycemic control was seen with liraglutide compared with the other GLP-1 treatment options; however, the two long-acting agents were superior to exenatide twice daily. All agents were well tolerated with most adverse events being mild or moderate in nature. The most common adverse event was transient nausea which typically resolved 4-8 weeks after treatment initiation. Long-acting agents had lower rates of nausea but an increased incidence of injection site reactions. Trials have suggested GLP-1 RAs may improve cardiovascular risk factors including blood pressure, lipid parameters and inflammatory markers. Future trials are needed to confirm the clinical outcomes of these agents. Overall, GLP-1 RAs will provide benefit for patients with T2DM intolerable to or not reaching glycemic goals with first-line agents, especially in patients in need of weight loss.

show abstract

“…Among patients (N=128) randomized to receive exenatide twice daily or glibenclamide for 1 year, exenatide twice daily significantly improved HOMA-B (Table 2; p<0.01), whereas glibenclamide had no significant effect on HOMA-B [34]. HOMA-B was significantly higher with exenatide twice daily compared with glibenclamide (p<0.05), demonstrating superior improvements with exenatide twice daily.…”

Section: Studymentioning

confidence: 98%

Effects of Glucagon-Like Peptide-1 Receptor Agonists on β-Cell Function in Patients with Type 2 Diabetes

Grandy¹,

Shaunik²

2015

J Diabetes Metab

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is characterized by insulin resistance and a progressive decline in pancreatic β-cell function. Over time, upregulation of insulin secretion is no longer sufficient to compensate for insulin resistance, leading to fasting hyperglycemia, while β-cell function continues to deteriorate. Effective treatments targeting the underlying pathophysiology of T2D involve early lifestyle interventions and a combination of therapies to counteract insulin resistance and progressive deterioration of β cells. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one class of antihyperglycemic agents that target multiple pathways, mediating clinical benefits for patients with T2D. This review summarizes the effects of treatment with various GLP-1RAs, including exenatide (twice daily and once weekly), liraglutide, dulaglutide, and lixisenatide, on β-cell function in patients with T2D. β-cell function was assessed in randomized controlled trials and their extension studies using a variety of methods, including glucose and arginine clamp techniques, proinsulin-to-insulin ratio, and homeostatic model assessment of β-cell function (HOMA-B). Exenatide twice daily and liraglutide both improved first-and second-phase insulin secretory responses. In addition, numerous studies reported significant improvements in HOMA-B with exenatide (twice daily and once weekly; range of relative change from baseline: +28-50%; range of absolute change: +5-40%) or liraglutide (range of change vs. placebo: +13-43%). Improvements in HOMA-B were also observed with the newer GLP-1RAs dulaglutide and lixisenatide. In contrast to the effects on HOMA-B, treatment with GLP-1RAs had a lesser effect on insulin sensitivity. Taken together, the results suggest that glucagon-like peptide-1 analogs have a greater effect on β-cell function than insulin sensitivity.

show abstract

Exenatide Versus Glibenclamide in Patients with Diabetes

Abstract: Both exenatide and glibenclamide gave a similar improvement of glycemic control, but only exenatide gave improvements of insulin resistance and beta-cell function, giving also a decrease of body weight and of inflammatory state.

Cited by 120 publications

References 41 publications

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

Effects of Glucagon-Like Peptide-1 Receptor Agonists on β-Cell Function in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About